Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02976441
Other study ID # 15-x135
Secondary ID
Status Withdrawn
Phase Early Phase 1
First received November 23, 2016
Last updated February 16, 2017
Start date January 2017
Est. completion date February 2018

Study information

Verified date February 2017
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators hypothesize that this study will show that sufficient lymphocyte stem cell can be harvested prior chemoradiation and be reinfused back after treatment, and at least 5 of the 10 patients (50%) will achieve an absolute increase of lymphocyte counts of 300 cells/mm^3 four weeks after stem cell reinfusion in high grade glioma patients.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 2018
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed newly diagnosed high grade glioma by pathology (WHO grade III or IV).

- At least 18 years of age.

- Karnofsky performance status = 60%

- Normal bone marrow and organ function as defined below:

- Absolute neutrophil count = 1,500/mcl

- Platelets = 100,000/mcl

- Hematocrit = 30%

- Absolute lymphocyte count = 1000/mcl Blood transfusions are permitted to allow potential participant to meet these criteria.

- Post-operative treatment plan must include standard radiation and temozolomide.

- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

- Prior treatment with radiation therapy, chemotherapy, immunotherapy, biologic agents (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK, or gene therapy), or hormonal therapy. Glucocorticoid therapy is allowed.

- Anti-VEGF therapy within 6 weeks of registration.

- A history of other malignancy = 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.

- Currently receiving any investigational agents that might affect lymphocytes. Patients receiving Novocure are allowed on study.

- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to filgrastim or plerixafor or other agents used in the study.

- Fresh CNS bleed as evident by MRI or CT.

- Contraindicated for anticoagulation.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.

- Known HIV-positivity.

Study Design


Intervention

Radiation:
Radiation therapy

Drug:
Temozolomide

Procedure:
Stem cell collection

Stem cell infusion


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of lymphocyte stem cell harvesting and reinfusion in patients as measured by the number of patients from whom 1-5x10e6 lymphocyte stem cells are collected and successfully reinfused without an adverse event The study will provide preliminary evidence of efficacy if =5 of 10 patients (50%) achieve an increase over baseline in absolute lymphocyte counts (ALC) =300 cells/mm3 at 4 weeks after reinfusion from their baseline lymphocyte counts. Completion of follow-up of all patients who received stem cell reinfusions (estimated to be 15 months)
Secondary Number of lymphocyte stem cells that can be harvested from this patient population Completion of follow-up of all patients who received stem cell reinfusions (estimated to be 15 months)
Secondary Proportion of patients who have an increase in lymphocyte of =300 cells/mm^3 after autologous stem cell reinfusion. 4 weeks after stem cell reinfusion
Secondary Duration of lymphocyte rise following stem cell reinfusion Up to 6 months after stem cell reinfusion (approximately 9 months)
Secondary Changes in lymphocyte subtypes following collection and reinfusion Lymphocyte subtypes will be monitored by flow cytometry at the time of stem cell collection, prior to autologous stem cell reinfusion, and then monthly for 6 months. Up to 6 months after stem cell reinfusion (approximately 9 months)
Secondary Changes in series of cytokine levels following collection and reinfusion Cytokine levels will be checked by ELISPOT at the time of stem cell collection, weekly during radiation therapy/temozolomide (up to 6 weeks), prior to autologous stem cell reinfusion, and then monthly for 6 months. Up to 6 months after stem cell reinfusion (approximately 9 months)
Secondary Safety and toxicities with stem cell collection and reinfusion as measured by grade and frequency of adverse events the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all adverse event/toxicity reporting. Up to 6 months after stem cell reinfusion (approximately 9 months)
See also
  Status Clinical Trial Phase
Terminated NCT02764151 - First in Patient Study for PF-06840003 in Malignant Gliomas Phase 1
Completed NCT00994071 - A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors Phase 1
Completed NCT02903784 - Neural Basis of Language Processing N/A
Terminated NCT01502605 - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas Phase 1
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT00705198 - Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) N/A
Completed NCT00165360 - Prolonged Daily Temozolomide for Low-Grade Glioma Phase 2
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Terminated NCT00389090 - A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Phase 2
Completed NCT00154375 - Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Phase 3
Completed NCT00001148 - Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor N/A
Completed NCT03722355 - Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Phase 3
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Recruiting NCT05686798 - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Phase 1
Active, not recruiting NCT03739372 - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma N/A
Recruiting NCT05624736 - Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Recruiting NCT05345002 - All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma Phase 2
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT00783393 - SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) Phase 2
Completed NCT03900689 - Social Determinants of Health in Glioblastoma Population